Top

Published in:

01-10-2020 | Glioma | Original Article

Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas

Authors: Xuanwei Zhang, Shuo Liu, Xu Zhao, Xiaobo Shi, Jing Li, Jia Guo, Gabriele Niedermann, Ren Luo, MD, Xiaozhi Zhang, MD

Published in: Strahlentherapie und Onkologie | Issue 10/2020

Abstract

Purpose

To extrapolate the infiltration levels of immune cells in patients with lower-grade gliomas (LGGs) using magnetic resonance imaging (MRI)-based radiomic features.

Methods

A retrospective dataset of 516 patients with LGGs from The Cancer Genome Atlas (TCGA) database was analysed for the infiltration levels of six types of immune cells using Tumor IMmune Estimation Resource (TIMER) based on RNA sequencing data. Radiomic features were extracted from 107 patients whose pre-operative MRI data are available in The Cancer Imaging Archive; 85 and 22 of these patients were assigned to the training and testing cohort, respectively. The least absolute shrinkage and selection operator (LASSO) was applied to select optimal radiomic features to build the radiomic signatures for extrapolating the infiltration levels of immune cells in the training cohort. The developed radiomic signatures were examined in the testing cohort using Pearson’s correlation.

Results

The infiltration levels of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils and dendritic cells negatively correlated with overall survival in the 516 patient cohort when using univariate Cox’s regression. Age, Karnofsky Performance Scale, WHO grade, isocitrate dehydrogenase mutant status and the infiltration of neutrophils correlated with survival using multivariate Cox’s regression analysis. The infiltration levels of the 6 cell types could be estimated by radiomic features in the training cohort, and their corresponding radiomic signatures were built. The infiltration levels of B cells, CD8+ T cells, neutrophils and macrophages estimated by radiomics correlated with those estimated by TIMER in the testing cohort. Combining clinical/genomic features with the radiomic signatures only slightly improved the prediction of immune cell infiltrations.

Conclusion

We developed MRI-based radiomic models for extrapolating the infiltration levels of immune cells in LGGs. Our results may have implications for treatment planning.

Available only for authorised users

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. https://doi.org/10.1093/neuonc/not151CrossRefPubMedPubMedCentral

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr. (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade Glioma. N Engl J Med 374(14):1344–1355. https://doi.org/10.1056/NEJMoa1500925CrossRefPubMedPubMedCentral

Macdonald DR, Gaspar LE, Cairncross JG (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27(5):573–574. https://doi.org/10.1002/ana.410270519CrossRefPubMed

van den Bent MJ (2014) Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 16(12):1570–1574. https://doi.org/10.1093/neuonc/nou297CrossRefPubMedPubMedCentral

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350. https://doi.org/10.1200/jco.2012.43.2229CrossRefPubMed

Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, Jiang T, Wu A (2014) Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 110(10):2560–2568. https://doi.org/10.1038/bjc.2014.162CrossRefPubMedPubMedCentral

Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19(1):20–27. https://doi.org/10.1038/nn.4185CrossRefPubMedPubMedCentral

Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A (2017) Tumor purity as an underlying key factor in glioma. Clin Cancer Res 23(20):6279–6291. https://doi.org/10.1158/1078-0432.Ccr-16-2598CrossRefPubMed

10.

Qian Z, Li Y, Fan X, Zhang C, Wang Y, Jiang T, Liu X (2018) Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. OncoImmunology 7(6):e1434466. https://doi.org/10.1080/2162402x.2018.1434466CrossRefPubMedPubMedCentral

11.

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278(2):563–577. https://doi.org/10.1148/radiol.2015151169CrossRefPubMed

12.

Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, Wang Y, Chen L, Mao Y (2017) Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol 27(8):3509–3522. https://doi.org/10.1007/s00330-016-4653-3CrossRefPubMed

13.

Li Y, Liu X, Xu K, Qian Z, Wang K, Fan X, Li S, Wang Y, Jiang T (2018) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol 28(1):356–362. https://doi.org/10.1007/s00330-017-4964-zCrossRefPubMed

14.

Qian Z, Li Y, Sun Z, Fan X, Xu K, Wang K, Li S, Zhang Z, Jiang T, Liu X, Wang Y (2018) Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction. Aging 10(10):2884–2899. https://doi.org/10.18632/aging.101594CrossRefPubMedPubMedCentral

15.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec J‑Y, Marabelle A, Massard C, Soria J‑C, Robert C, Paragios N, Deutsch E, Ferté C (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD‑1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19(9):1180–1191. https://doi.org/10.1016/S1470-2045(18)30413-3CrossRefPubMed

16.

Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, Rao G, Rao A (2017) Tumor image-derived texture features are associated with CD3 T‑cell infiltration status in glioblastoma. Oncotarget 8(60):101244–101254. https://doi.org/10.18632/oncotarget.20643CrossRefPubMedPubMedCentral

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77(21):e108–e110. https://doi.org/10.1158/0008-5472.Can-17-0307CrossRefPubMedPubMedCentral

18.

Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS (2016) Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 17(1):174. https://doi.org/10.1186/s13059-016-1028-7CrossRefPubMedPubMedCentral

19.

Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F (2013) The cancer imaging archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26(6):1045–1057. https://doi.org/10.1007/s10278-013-9622-7CrossRefPubMedPubMedCentral

20.

Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby JS, Freymann JB, Farahani K, Davatzikos C (2017) Advancing the cancer genome atlas glioma MRI collections with expert segmentation labels and radiomic features. Sci Data 4:170117. https://doi.org/10.1038/sdata.2017.117CrossRefPubMedPubMedCentral

21.

Bakas S, Zeng K, Sotiras A, Rathore S, Akbari H, Gaonkar B, Rozycki M, Pati S, Davatzikos C (2016) GLISTRboost: combining multimodal MRI segmentation, registration, and biophysical tumor growth modeling with gradient boosting machines for glioma segmentation. In: Brainlesion: glioma, multiple sclerosis, stroke and traumatic brain injuries. BrainLes (Workshop), vol 9556, pp 144–155 https://doi.org/10.1007/978-3-319-30858-6_1CrossRef

22.

Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Soft 33(1):1–22CrossRef

23.

Simon N, Friedman J, Hastie T, Tibshirani R (2011) Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Soft 39(5):1–13. https://doi.org/10.18637/jss.v039.i05CrossRef

24.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautes-Fridman C (2019) The clinical role of the TME in solid cancer. Br J Cancer 120(1):45–53. https://doi.org/10.1038/s41416-018-0327-zCrossRefPubMed

25.

Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734. https://doi.org/10.1038/nrclinonc.2017.101CrossRefPubMed

26.

Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF (2014) Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res 20(1):187–198. https://doi.org/10.1158/1078-0432.Ccr-13-1279CrossRefPubMed

27.

Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML (1999) Neutrophil infiltration into human gliomas. Acta Neuropathol 98(4):349–354. https://doi.org/10.1007/s004010051093CrossRefPubMed

28.

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H (2017) Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 127(4):1425–1437. https://doi.org/10.1172/JCI90644CrossRefPubMedPubMedCentral

29.

Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby J, Freymann J, Farahani K, Davatzikos C (2017) Segmentation labels and radiomic features for the pre-operative scans of the TCGA-LGG collection https://doi.org/10.7937/K9/TCIA.2017.GJQ7R0EFCrossRef

30.

Bakas S, Akbari H, Sotiras A et al (2017) Table 3 Generated radiomic features and their description. https://www.nature.com/articles/sdata2017117/tables/4

Title: Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas
Authors: Xuanwei Zhang
Shuo Liu
Xu Zhao
Xiaobo Shi
Jing Li
Jia Guo
Gabriele Niedermann
Ren Luo, MD
Xiaozhi Zhang, MD
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Glioma
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Glioma
Glioma
Published in: Strahlentherapie und Onkologie / Issue 10/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01584-1

At a glance: The STEP trials

Springer Medicine

Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

The role of radiomics in prostate cancer radiotherapy

Unterschiede in der Lebensqualität über 5 Jahre nach Therapie des lokal begrenzten Prostatakarzinoms mit verschiedenen Behandlungsoptionen

Artificial intelligence and radiomics for radiation oncology

Radiomic biomarkers for head and neck squamous cell carcinoma

Einfluss der Behandlungscompliance auf den Erfolg der Radiochemotherapie des Analkarzinoms

Die Herzmortalität nach Strahlentherapie, Chemotherapie und endokriner Therapie des Mammakarzinoms